Name: U.S., Pfizer, BioNTech reach deal to distribute COVID-19 vaccine
Brand: upi.com
SKU: upi-com-451
Availability: OnlineOnly

critic

U.S., Pfizer, BioNTech reach deal to distribute COVID-19 vaccine

preview

TrendingAdvertisementHealth and Human Services Secretary Alex Azar speaks to reporters in the Rose Garden of the White House on May 15. File Photo by Stefani Reynolds/UPI |The U.S. government on Wednesday announced it has entered an agreement with drugmaker Pfizer and partner BioNTech to produce and deliver 100 million doses of a vaccine by the end of the year.Officials said the Defense and Health and Human Services departments are parties to the agreement, which also allows the government to acquire an additional 500 million doses. After it is approved, the vaccine will be available at no cost, they said.AdvertisementThe $2 billion deal involves the BNT162 vaccine candidate being developed by Pfizer and BioNTech, the companies said.The goal of Operation Warp Speed, the federal and private venture to develop a COVID-19 vaccine, is to begin delivering 300 million doses next year."Through Operation Warp Speed, we are assembling a portfolio of vaccines to increase the odds that the American people will have at least one safe, effective vaccine as soon as the end of this year," HHS Secretary . "Depending on success in clinical trials, today's agreement will enable the delivery of approximately 100 million doses of vaccine being developed by Pfizer and BioNTech."AdvertisementPfizer Chairman and CEO Albert Bourla said the company is committed to "making the impossible possible" by producing a vaccine in record time."We made the early decision to begin clinical work and large-scale manufacturing at our own risk to ensure that product would be available immediately if our clinical trials prove successful and an Emergency Use Authorization is granted," he in a statement.Pfizer Chief Business Officer told a congressional committee he's confident that scientists will find an effective vaccine."I believe the probability is high that the biopharmaceutical industry will be able to develop one or more safe and effective vaccines," he said.Wednesday's agreement comes two days after Pfizer and BioNTech positive testing results for their BNT162 candidates. They're evaluating at least four potential vaccines in the BNT16 program, all based on the messenger RNA technique.Federal officials said delivery of an approved vaccine would begin at the government's direction beginning in the fourth quarter of 2020. Although the vaccine would be available at no cost to consumers, officials said healthcare professionals could charge insurers for related costs.HHS said the Pfizer/BioNTech vaccines are being developed without financial support from the government.AdvertisementAdvertisementAdvertisementAdvertisement

TrendingAdvertisementHealth and Human Services Secretary Alex Azar speaks to reporters in the Rose Garden of the White House on May 15. File Photo by Stefani Reynolds/UPI |The U.S. government on Wednesday announced it has entered an agreement with drugmaker Pfizer and partner BioNTech to produce and deliver 100 million doses of a vaccine by the end of the year.Officials said the Defense and Health and Human Services departments are parties to the agreement, which also allows the government to acquire an additional 500 million doses. After it is approved, the vaccine will be available at no...

public

Don Jacobson

upi.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

U.S., Pfizer, BioNTech reach deal to distribute COVID-19 vaccine

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS